Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2022

Open Access 01-12-2022 | Histiocytosis | Research

Rosai–Dorfman–Destombes disease of the nervous system: a systematic literature review

Authors: Ruham Alshiekh Nasany, Anne S. Reiner, Jasmine H. Francis, Oussama Abla, Katherine S. Panageas, Eli L. Diamond

Published in: Orphanet Journal of Rare Diseases | Issue 1/2022

Login to get access

Abstract

Background

Rosai–Dorfman–Destombes disease (RDD) is a rare histiocytic disorder with heterogeneous clinical manifestations and rare neurologic involvement. The existing clinical literature about neurologic RDD has yet to be critically examined.

Methods

We performed a four-database English-language systematic literature search for cases of RDD neurohistiocytosis, excluding secondary literature. Individual patient data for neurologic symptoms, disease sites, treatments, and responses were captured. Responses to first-line and second-line surgical interventions, post-surgical radiotherapy, and systemic therapies were analyzed.

Results

Among 4769 articles yielded by literature search, 154 articles were fully reviewed, containing data on 224 patients with neurologic RDD. 128 (83.1%) articles were single case reports. 149 (66.5%) patients were male, 74 (33.5%) female, with a median age of 37.6 years (range 2–79). Presenting neurologic symptoms included headache (45.1%), focal neurological deficits (32.6%), visual symptoms (32.1%), and seizures (24.6%). RDD involvement was multifocal in 32 (14.3%) cases. First-line treatment involved resection in 200 (89.6%) patients, with subsequent progression in 52 (26%), including 41 (78.8%) with unifocal disease. No difference was observed in progression-free survival comparing post-operative radiotherapy to no radiotherapy following partial resection. Chemotherapy given alone as first-line treatment led to complete or partial response in 3/7(43%) patients. Second-line treatments led to complete or partial response in 18/37(37.5%) patients. Mutational data were reported on 10 patients (4.46%).

Conclusions

This review highlights the limited published data about neurologic RDD, which presents with varied symptomatology and outcome. Further study is needed about its mutational landscape, and more effective therapies are needed for recurrent and refractory disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Destombes P. [Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases)]. Bull Soc Pathol Exot Filiales. 1965;58(6):1169–75.PubMed Destombes P. [Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases)]. Bull Soc Pathol Exot Filiales. 1965;58(6):1169–75.PubMed
2.
go back to reference Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63–70.PubMed Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63–70.PubMed
3.
go back to reference Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder. Analysis of 34 cases. Cancer. 1972;30(5):1174–88.CrossRef Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder. Analysis of 34 cases. Cancer. 1972;30(5):1174–88.CrossRef
4.
go back to reference Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7(1):19–73.PubMed Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7(1):19–73.PubMed
5.
go back to reference Vaiselbuh SR, et al. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61(7):1329–35.CrossRef Vaiselbuh SR, et al. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61(7):1329–35.CrossRef
6.
go back to reference Abla O, et al. Consensus recommendations for the diagnosis and clinical management of Rosai–Dorfman–Destombes disease. Blood. 2018;131(26):2877–90.CrossRef Abla O, et al. Consensus recommendations for the diagnosis and clinical management of Rosai–Dorfman–Destombes disease. Blood. 2018;131(26):2877–90.CrossRef
7.
go back to reference Diamond EL, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–65.CrossRef Diamond EL, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–65.CrossRef
8.
go back to reference Cooper SL, Jenrette JM. Rosai–Dorfman disease: management of CNS and systemic involvement. Clin Adv Hematol Oncol. 2012;10(3):199–202.PubMed Cooper SL, Jenrette JM. Rosai–Dorfman disease: management of CNS and systemic involvement. Clin Adv Hematol Oncol. 2012;10(3):199–202.PubMed
9.
go back to reference Sandoval-Sus JD, et al. Rosai–Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine (Baltimore). 2014;93(3):165–75.CrossRef Sandoval-Sus JD, et al. Rosai–Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine (Baltimore). 2014;93(3):165–75.CrossRef
10.
go back to reference Akl E et al. Cochrane handbook for systematic reviews of interventions. 2019. Akl E et al. Cochrane handbook for systematic reviews of interventions. 2019.
11.
go back to reference Bramer WM, et al. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–3.CrossRef Bramer WM, et al. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–3.CrossRef
12.
go back to reference Tian Y, et al. Rosai–Dorfman disease involving the central nervous system: seven cases from one institute. Acta Neurochir. 2015;157(9):1565–71.CrossRef Tian Y, et al. Rosai–Dorfman disease involving the central nervous system: seven cases from one institute. Acta Neurochir. 2015;157(9):1565–71.CrossRef
13.
go back to reference Kelly WF, Bradey N, Scoones D. Rosai–Dorfman disease presenting as a pituitary tumour. Clin Endocrinol (Oxf). 1999;50(1):133–7.CrossRef Kelly WF, Bradey N, Scoones D. Rosai–Dorfman disease presenting as a pituitary tumour. Clin Endocrinol (Oxf). 1999;50(1):133–7.CrossRef
14.
go back to reference Hong CS, et al. Redefining the prevalence of dural involvement in Rosai–Dorfman disease of the central nervous system. World Neurosurg. 2016;90:702.e13-702.e20.CrossRef Hong CS, et al. Redefining the prevalence of dural involvement in Rosai–Dorfman disease of the central nervous system. World Neurosurg. 2016;90:702.e13-702.e20.CrossRef
15.
go back to reference Bhatia A, et al. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol. 2020;22:979–92.CrossRef Bhatia A, et al. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol. 2020;22:979–92.CrossRef
16.
go back to reference Cohen Aubart F, et al. Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology. 2020;95(20):e2746–54.CrossRef Cohen Aubart F, et al. Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology. 2020;95(20):e2746–54.CrossRef
17.
go back to reference Yeh EA, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer. 2018;65(1): e26784.CrossRef Yeh EA, et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer. 2018;65(1): e26784.CrossRef
18.
go back to reference Porto L, et al. Central nervous system imaging in childhood Langerhans cell histiocytosis—a reference center analysis. Radiol Oncol. 2015;49(3):242–9.CrossRef Porto L, et al. Central nervous system imaging in childhood Langerhans cell histiocytosis—a reference center analysis. Radiol Oncol. 2015;49(3):242–9.CrossRef
19.
go back to reference Grois NMDP, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873-881.e1.CrossRef Grois NMDP, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873-881.e1.CrossRef
20.
go back to reference Abla O, et al. Central nervous system juvenile xanthogranuloma after langerhans cell histiocytosis. Pediatr Blood Cancer. 2013;60(2):342–3.CrossRef Abla O, et al. Central nervous system juvenile xanthogranuloma after langerhans cell histiocytosis. Pediatr Blood Cancer. 2013;60(2):342–3.CrossRef
21.
go back to reference Meshkini A, et al. Systemic juvenile xanthogranuloma with multiple central nervous system lesions. J Cancer Res Ther. 2012;8(2):311–3.CrossRef Meshkini A, et al. Systemic juvenile xanthogranuloma with multiple central nervous system lesions. J Cancer Res Ther. 2012;8(2):311–3.CrossRef
22.
go back to reference Picarsic J, et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun. 2019;7(1):168–168.CrossRef Picarsic J, et al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun. 2019;7(1):168–168.CrossRef
23.
go back to reference Shanmugam V, et al. Rosai–Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol. 2016;10(3):394–9.CrossRef Shanmugam V, et al. Rosai–Dorfman disease harboring an activating KRAS K117N missense mutation. Head Neck Pathol. 2016;10(3):394–9.CrossRef
24.
go back to reference Abla O, Picarsic J. Rosai–Dorfman disease. In: Abla O, Janka G, editors. Histiocytic disorders. Cham: Springer; 2018. p. 339–60.CrossRef Abla O, Picarsic J. Rosai–Dorfman disease. In: Abla O, Janka G, editors. Histiocytic disorders. Cham: Springer; 2018. p. 339–60.CrossRef
25.
go back to reference Ng Wing Tin S, et al. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. Orphanet J Rare Dis. 2011;6:83.CrossRef Ng Wing Tin S, et al. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. Orphanet J Rare Dis. 2011;6:83.CrossRef
26.
go back to reference Barkaoui MA, et al. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. Br J Haematol. 2020;191:825–34.CrossRef Barkaoui MA, et al. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. Br J Haematol. 2020;191:825–34.CrossRef
27.
go back to reference Dhall G, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72–9.CrossRef Dhall G, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008;50(1):72–9.CrossRef
28.
go back to reference Razanamahery J, et al. Histology of Rosai–Dorfman disease in a subset of patients with Erdheim–Chester disease: a distinct entity mainly driven by Map2k1. Pediatr Blood Cancer. 2019;66:S37–8. Razanamahery J, et al. Histology of Rosai–Dorfman disease in a subset of patients with Erdheim–Chester disease: a distinct entity mainly driven by Map2k1. Pediatr Blood Cancer. 2019;66:S37–8.
29.
go back to reference Gaurav G, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai–Dorfman disease. Haematologica. 2020;105(2):348–57.CrossRef Gaurav G, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai–Dorfman disease. Haematologica. 2020;105(2):348–57.CrossRef
30.
go back to reference Elshikh M, et al. Disease characteristics, radiologic patterns, comorbid diseases, and ethnic differences in 32 patients with Rosai–Dorfman disease. J Comput Assist Tomogr. 2020;44(3):450–61.CrossRef Elshikh M, et al. Disease characteristics, radiologic patterns, comorbid diseases, and ethnic differences in 32 patients with Rosai–Dorfman disease. J Comput Assist Tomogr. 2020;44(3):450–61.CrossRef
Metadata
Title
Rosai–Dorfman–Destombes disease of the nervous system: a systematic literature review
Authors
Ruham Alshiekh Nasany
Anne S. Reiner
Jasmine H. Francis
Oussama Abla
Katherine S. Panageas
Eli L. Diamond
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2022
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-022-02220-0

Other articles of this Issue 1/2022

Orphanet Journal of Rare Diseases 1/2022 Go to the issue